Alpha erythropoietin in the management of anaemia of prematurity: a report of three cases in Nigeria.
Anaemia of prematurity is a common problem encountered in most special care baby units warranting often repeated blood transfusions with its inherent dangers. We present three patients in Nigeria who were very low birth weight premature babies on whom recombinant erythropoietin was used as an efficient replacement for blood transfusions. All three patients showed a progressive drop in haemoglobin concentration from the first to the sixth to eight week of life with development of heamic murmurs and insignificant reticulocyte responses, and were planned for transfusion therapy. The parents of all the patients strongly refused transfusion therapy (one on religious grounds) warranting the use of recombinant erythropoietin to which there was a significant response in all three patients with elevation of haemoglobin concentration, PCV, and reticulocyte counts, and obviating the planned transfusions. No significant side effects were also noticed. We suggest further controlled trials to establish this mode of therapy.
Awogu
A U
AU
Dept of Peadiatrics, First Consultants Medical Cenre, Ikoyi, Lagos.
Abohweyere
A E J
AE
D000751:Anemia, Neonatal / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male; D009549:Nigeria; D011994:Recombinant Proteins; D017701:Reticulocyte Count
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin